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ABSTRACT 1 
 2 
The identification of biomarkers for the early diagnosis of schizophrenia that could inform 3 
novel treatment developments is an important objective of current research. This paper will 4 
summarize recent work that has investigated changes in oscillatory activity and event-related 5 
potentials with Electro/Magnetoencephalography (EEG/MEG) in participants at high-risk for 6 
the development of schizophrenia, highlighting disruptions in sensory and cognitive 7 
operations prior to the onset of the syndrome. Changes in EEG/MEG-data are consistent with 8 
evidence for alterations in Glutamatergic and GABAergic neurotransmission as disclosed by 9 
Magnetic Resonance Spectroscopy and brain stimulation, indicating changes in 10 
Excitation/Inhibition Parameters prior to the onset of psychosis. Together these data 11 
emphasize the importance of research into neuronal dynamics as a crucial approach to 12 
establish functional relationships between impairments in neural circuits and emerging 13 
psychopathology that together could be fundamental for early intervention and the 14 
identification of novel treatments for emerging psychosis.  15 
 16 
KEYWORDS 17 
Schizophrenia, Neuroscience, Prodrome, Oscillations, E/I-Balance, Electrophysiology 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
4 
 
1. INTRODUCTION 27 
 28 
1.1 Schizophrenia and Prodrome 29 
Schizophrenia is a severe psychiatric disorder that is associated with a life-time prevalence of 30 
approximately 1 % that continues to be a significant challenge for efforts to improve outcome 31 
and treatment. This is because the pathophysiological processes that give rise to both the 32 
psychophathological features (positive, negative and disorganized symptoms) as well as the 33 
pronounced cognitive deficits remain to be elucidated (Insel, 2010). Accordingly, current 34 
treatment options are largely focussed on targeting symptomatic manifestations once the 35 
disorder is fully manifested while interventions that correct fundamental circuit abnormalities 36 
remain unavailable.  37 
Current theories have highlighted that one possible reason for the emergence of psychosis 38 
and associated perceptual and cognitive deficits is to be found in the disruption of neural 39 
dynamics that coordinate brain activity in large-scale networks (Uhlhaas & Singer, 2011). 40 
One candidate mechanism for this process is the synchronization of oscillatory responses at 41 
both low- (delta [1-3 Hz], theta [3-8Hz] and alpha [8-12 Hz]) and high- (beta [13-30 42 
Hz]/gamma [30-100 Hz]) frequencies that have been associated with a wide-range of 43 
cognitive and sensory tasks during normal brain functioning (Buzsaki & Draguhn, 2004; 44 
Fries, 2009).  45 
Importantly, evidence has emerged suggesting that ScZ is associated with an impairment in 46 
both amplitude and precision of synchronized rhythmic activity (Uhlhaas & Singer, 2010), 47 
consistent with alterations in circuit mechanisms in the disorder that give rise to generation of 48 
neural oscillations during normal brain functioning (Lewis, Curley, Glausier, & Volk, 2012). 49 
Crucial variables for the generation of precise rhythmic activity are the balance between the 50 
efficiency of excitation/inhibition (E/I) balance (Sohal, Zhang, Yizhar, & Deisseroth, 2009; 51 
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Wang, 2010; Whittington, Traub, & Jefferys, 1995) and the layout of long-range connections, 52 
both excitatory and inhibitory, held responsible for the synchronization of spatially 53 
segregated cell groups (Engel, Konig, Kreiter, & Singer, 1991; Melzer, et al., 2012). 54 
Accordingly, investigations into alterations of neural oscillations may allow a unique 55 
opportunity for establishing a translational paradigm, whereby electrophysiological variables 56 
can be linked to basic circuit deficits that can guide development of novel treatment options.  57 
Experimental and theoretical data highlighted the contribution of GABAergic interneurons 58 
towards the generation of high-frequency oscillations (Wang & Buzsaki, 1996)(Traub et al., 59 
2004). Parvalbumin-positive  (PV+) cells are one class of interneurons that have been 60 
traditionally involved in the generation of gamma-band oscillations through PV+-mediated 61 
feedback inhibition of principal cell activity (Sohal, et al., 2009). More recently, a second 62 
class of interneurons that express somatostatin (SST) has been shown to be relevant for the 63 
generation of gamma-band oscillations (Veit, Hakim, Jadi, Sejnowski, & Adesnik, 2017) 64 
while previous evidence linked SST-cells predominantly to the generation of low-frequency 65 
rhythms (Urban-Ciecko & Barth, 2016) .  66 
Moreover, there is evidence for a specific role of glutamatergic inputs to PV interneurons for 67 
the generation of coordinated network activity. Carlén et al. (Carlen, et al., 2011) showed that 68 
the deletion of the NMDA-NR1 receptors on PV interneurons in mice is associated with an 69 
increase in spontaneous gamma-band activity in somatosensory cortex, while gamma-band 70 
activity during sensory stimulation was reduced. Similarly, the activation of AMPA-receptors 71 
is essential for the emergence of high-frequency activity as indicated by evidence 72 
highlighting that a reduction of the GLuR-D receptor leads to a decrease of AMPA-mediated 73 
currents in PV interneurons and reduced power of oscillations in the 20–80 Hz range (Fuchs, 74 
et al., 2001). However, the relative contribution of both NMDA- and AMPA-Rs towards 75 
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high-frequency oscillations remains an open question. One possibility is that NMDA-Rs 76 
provide more sustained excitatory drive to PV+ cells (Compte, Brunel, Goldman-Rakic, & 77 
Wang, 2000), while AMPAR mediated-EPSCs provide faster excitatory inputs to the 78 
interneurons that are a prerequsisite for the generation gamma-band oscillations (Kirli, 79 
Ermentrout, & Cho, 2014; Rotaru, Yoshino, Lewis, Ermentrout, & Gonzalez-Burgos, 2011). 80 
 Data from post-mortem (Gonzalez-Burgos & Lewis, 2008), genetic (Pocklington, et al., 81 
2015) and animal models of ScZ (Behrens, Ali, & Dugan, 2008; Lodge, Behrens, & Grace, 82 
2009) suggest that pathophysiological processes provide converging evidence that 83 
GABAergic and Glutmatatergic neurotransmission is impaired in ScZ. Thus, there are 84 
consistent findings for a reduction in transcript and protein-levels of PV+cells across cortical 85 
regions in ScZ as well as for reduced levels of the key GABA-synthesizing enzyme GAD67 86 
(for a review see (Lewis, Hashimoto, & Volk, 2005)). It is currently, unclear, however, 87 
whether the alterations in GABAerig neurotransmission are a primary impairment or whether 88 
these alterations are secondary deficits in excitatory pyramidal cells (Lewis, et al., 2012). 89 
Moreover, it is conceivable that other variables, such as oxidative stress, may lead to 90 
downstream deficits in PV+ cells. Steullet et al. (2017) examined several animal models 91 
characterized by either genetic and/or environmental risk-factors  in relationship to PV+ cells 92 
and oxidative stress.  Across all animal models, oxidative stress was negatively correlated 93 
with the integrity of PV+ cells.  94 
Further evidence for a dysregulation of E/I-balance in ScZ parameters comes from studies 95 
that have examined Glutamate and GABA-levels with Magnetic Resonance Spectroscopy 96 
(MRS). The earliest MRS-studies were focusing mainly on high concentration brain 97 
metabolites such as N-Acetylaspartic acid (NAA), creatine (Cr) and choline (Cho) (Jessen et 98 
al., 2006; Wood et al., 2010; Yoo et al., 2009). More recent efforts have been directed 99 
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primarily at measures of GABA, Glutamate or Glutamate + Glutamine (Glx) (P. Fusar-Poli 100 
2011; Kegeles et al. 2012; Tandon et al. 2013; Natsubori et al. 2014; Liemburg et al. 2016; 101 
Fuente-sandoval et al. 2015; Menschikov et al. 2016; Modinos et al. 2017). Across studies, 102 
elevated glutamate-levels have been demonstrated in cortical and subcortical regions in  103 
clinical high-risk (CHR)-participants (Merritt, Egerton, Kempton, Taylor, & McGuire, 2016) 104 
while the pattern of changes GABA-levels is inconsistent (Egerton, Modinos, Ferrera, & 105 
McGuire, 2017). As MRS-measures of GABA and glutamate could provide important 106 
insights into alterations in E/I-balance parameters in ScZ, the combination with EEG/MEG-107 
parameters is potentially informative about the physiological origin of impairments in neural 108 
dynamics in ScZ. 109 
 110 
1.2 Towards Pre-Emptive Psychiatry and Biomarkers for Early Intervention   111 
Recent efforts in ScZ-research have focussed on the possibility of identifying individuals who 112 
have a high risk of developing psychosis and the development of appropriate strategies for 113 
risk prediction and early intervention (Fusar-Poli, et al., 2013; McGorry, et al., 2009). This 114 
approach is based on long-standing evidence that the manifestation of ScZ is preceded by a 115 
prodromal period of up to 5 years during which subtle behavioural changes, cognitive 116 
impairments and sub-threshold psychotic symptoms emerge (Klosterkotter, Hellmich, 117 
Steinmeyer, & Schultze-Lutter, 2001; Yung & McGorry, 1996). As a result, clinical high-risk 118 
criteria (CHR) have been developed based on the presence of attenuated psychotic symptoms 119 
(Yung, et al., 2005) as well as self-experienced perceptual and cognitive anomalies, 120 
representing the earliest manifestation of psychosis risk (Schultze-Lutter, Ruhrmann, 121 
Berning, Maier, & Klosterkotter, 2010). Recent data from several high-risk studies have 122 
shown that CHRs are associated with transition rates between 10 and 30% over a two year 123 
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period (Fusar-Poli, et al., 2013). While screening procedures are characterized by sufficient 124 
diagnostic accuracy to detect at-risk individuals (Fusar-Poli, et al., 2015), clinical criteria are 125 
currently not sensitive and specific enough to predict psychosis-risk on an individual level, a 126 
key objective for early intervention research. Accordingly, biomarkers may be required to 127 
boost prediction and allow insights into the underlying neurobiology of the at-risk state that 128 
could guide the search for targeted interventions.  129 
 130 
                                                   Enter Figure 1 about here 131 
 132 
The search for biomarkers has so far focussed on anatomical parameters, such as volumetric 133 
studies of grey matter (GM), that have revealed reductions in several brain regions prior to 134 
the onset of psychosis in CHR-participants that predict transition to ScZ (Koutsouleris, et al., 135 
2009; Pantelis, et al., 2003). This view is consistent with the hypothesis that developmental 136 
perturbations of synaptic pruning may give rise to the onset of psychosis (Feinberg, 1982). In 137 
addition, structural magnetic resonance studies of white-matter volume and organization 138 
(Carletti, et al., 2012) as well as functional magnetic resonance imaging (fMRI) (Anticevic, et 139 
al., 2015) have provided data supporting the hypothesis that anatomical and functional large-140 
scale networks are disrupted prior to psychosis-onset.  141 
A limitation of these approaches, however, is the absence of direct measurements of neuronal 142 
activity that provide sufficient temporal resolution as well as the difficulty of relating such 143 
measures to basic circuit mechanisms, a prerequisite for translational research (Uhlhaas & 144 
Singer, 2012). In the current paper, we will outline the rationale for applying 145 
electrophysiological techniques, such as electro/magnetoencephalography (EEG/MEG), in 146 
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combination with brain stimulation and MRS to identify novel biomarkers for early diagnosis 147 
and interventions in ScZ. In the first part of the paper, we will discuss the evidence for 148 
changes in neural oscillations and event-related potentials/fields (ERP/ERFs) in CHR-149 
participants followed by studies with transcranial magnetic and direct current stimulation 150 
(TMS/tDCS). In the second part, evidence on changes in GABA and Glutamatergic 151 
neurotransmission will be reviewed that are relevant for understanding changes in E/I-152 
balance alterations as causative factors in emerging psychosis. Finally, we will provide an 153 
assessment of the current evidence on changes in neuronal dynamics in the prodrome of ScZ 154 
with recommendations for future work and links with pre-clinical research.  155 
 156 
2. Electrophysiology of the Prodrome  157 
 158 
2.1 ERPs in CHR-Participants  159 
ERPs/ERFs are time-locked brain responses to internal or external stimuli and provide a non-160 
invasive method to identify neural correlates of cognitive and perceptual processes (Luck 161 
2012) (for a review of ERP-findings in CHR-participants see Bodatsch et al., 2015). Several 162 
ERP/ERF components have been studied extensively in patients with ScZ to gain insights 163 
into dysfunctions of basic sensory and higher cognitive processing. Evidence shows that there 164 
are impairments in ERP/ERFs at early latencies, such as in the P50 (Bramon et al. 2004), 165 
N100 (Ford et al. 2014), P100 (Earls, Curran, & Mittal, 2016) and mismatch negativity 166 
(MMN) (Umbricht and Krljes 2005), that have been linked to deficits during the encoding of 167 
information, while impairments in the P300 (Bramon et al. 2004), for example, likely reflect 168 
failures in higher cognitive processes.  169 
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One potential biomarker for psychosis is the auditory MMN or its magnetic counterpart 170 
MMNm, an ERP/ERF that is elicited automatically by a violation of a previously established 171 
auditory regularity (Näätänen et al. 2007; Näätänen, Gaillard, and Mäntysalo 1978). Current 172 
evidence suggest that N-methyl-D-aspartate receptors (NMDA-R) (Javitt et al. 1996) as well 173 
as STS-expressing interneurons play a major role in the generation of MMN-responses  174 
(Hamm & Yuste, 2016).  175 
In ScZ, MMN amplitudes are consistently reduced across a range of stimulation protocols   176 
(for a review, see Umbricht and Krljes 2005) and have been associated with a reduction in 177 
both cognition and social functioning (Baldeweg and Hirsch 2015; Light and Braff 2005). 178 
Evidence from computational modeling and EEG/MEG-data suggests that dysfunctional 179 
predictive processes may underlie MMN-deficits (Sauer et al. 2017; Rentzsch et al. 2015; 180 
Wacongne 2015).   181 
Several recent studies investigated MMN-responses in CHR-participants, indicating impaired 182 
MMN responses to duration and frequency deviants (Atkinson et al., 2012; Carrion et al., 183 
2015; Hsieh et al., 2012; Jahshan et al., 2012; Koshiyama et al., 2016; Perez et al., 2014b; 184 
Shaikh et al., 2012; Shin et al., 2009; Solis-Vivanco et al., 2014). However, not all studies 185 
have confirmed this finding (Brockhaus-Dumke et al. 2005; Bodatsch et al. 2011; 186 
Mondragón-Maya et al. 2013; Higuchi et al. 2013) and there is evidence to suggest that 187 
MMN-deficits are primarily observed in CHR-participants who transition to psychosis 188 
(CHR+) (Higuchi et al. 2013; Shaikh et al. 2012 but see Atkinson et al. 2017 for a different 189 
finding.)  190 
In addition to MMN-impairments, sensory gating, a pre-attentive measure of auditory 191 
processing that involves presentation of two clicks within a 500 ms window, has been 192 
consistently found to be impaired in ScZ (Brockhaus-Dumke, et al., 2008). There is an 193 
established link between P50 sensory-gating and cholinergic neurotransmission as reflected 194 
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by genetic data linking the α-7 nicotinic receptor and P50 responses (Martin & Freedman, 195 
2007).  196 
The auditory N100 has also been utilized to explore sensory gating deficits in ScZ. Currently, 197 
there is mixed evidence for P50 and N100 sensory gating deficits in CHR-participants, with 198 
some studies reporting evidence for a reduction (Brockhaus-Dumke et al. 2008), while others 199 
could not distinguish CHR from both ScZ-patients and controls (van Tricht et al. 2015; Hsieh 200 
et al. 2012; Shin, Kim, et al. 2012). Moreover, conflicting findings exist on the predictive 201 
utility of P50 and N100 measures for distinguishing CHR+ (converter) from CHR− (non-202 
converter) participants (Brockhaus-Dumke et al. 2008; van Tricht et al. 2011; van Tricht et al. 203 
2015; Shaikh et al. 2015).  204 
In addition, there is an increasing interest to explore sensory attenuation of ERPs/ERFs and 205 
by calculating the N1/P1 difference between experimental conditions that involve passive 206 
sensory stimulation and an active condition during which the incoming stimulus is self-207 
generated (Cao, Thut, and Gross 2017; Hughes and Waszak 2011). Impaired auditory sensory 208 
attenuation has been observed in ScZ and is thought to be related to impaired corollary 209 
discharge processes which lead to certain clinical symptoms, such as delusion of control or 210 
hallucinations (Ford et al. 2014; Perez et al. 2012). Perez et al. (Perez et al. 2012) explored 211 
N1 suppression in CHR-participants and found that the degree of N1 suppression was 212 
intermediate between the healthy controls and ScZ-patients. Deficits in the auditory N1 in 213 
CHR-participants have been also related to cortical thinning in auditory regions (Shin, Jung, 214 
et al. 2012). 215 
In addition to auditory processing, there is increasing evidence for impaired early visual 216 
information processing in ScZ patients as reflected by reductions in the P100 (Earls, Curran, 217 
and Mittal 2016; Sehatpour et al. 2010) and N170 (McCleery et al. 2015). In CHR-218 
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participants, there is currently only preliminary evidence for reduced P100 and N170 219 
amplitude during face processing (Wölwer et al. 2012).  220 
The P300 is a positive waveform which has been was identified with cognitive processing 221 
(Polich & Kok, 1995), such as attention and memory updating. The P300 is modulated by 222 
multiple neurotransmitter systems (Huang, Chen, and Zhang 2015), predominantly 223 
GABAergic (Watson et al. 2009) and dopaminergic neurotransmission (Pogarell et al. 2011).  224 
There is emerging evidence that CHR-participants are characterized by a deficit in the 225 
amplitude of the auditory P3a (Atkinson, Michie, & Schall, 2012; Bramon, et al., 2008; 226 
Mondragón-Maya, et al., 2013; Nagai, et al., 2013) that is associated with an increased risk 227 
for developing psychosis (Kim, Lee, Lee, Kim, & Kwon, 2015). Besides the auditory P300, 228 
there is preliminary evidence for a reduction of the visual P300 in CHR participants as well 229 
(Lee, Namkoong, Cho, Song, & An, 2010).   230 
                                                              Enter Figure 2 about here 231 
 232 
2.2 Neural Oscillations in CHR-Participants 233 
Spectral signatures of EEG/MEG-data have gained increasing interest as a potential 234 
biomarker in CHR-participants. One approach has been the analysis of resting-state activity. 235 
A robust finding in established ScZ is the increase of slow-wave activity as reflected by 236 
elevated delta and theta-band power  (Ranlund et al., 2014; see Boutros et al., 2008 for a 237 
meta-analysis;) and increased connectivity (Andreou, et al., 2015).. In CHR-participants, 238 
findings from several EEG-studies have failed to observe similar effects (Wuebben and 239 
Winterer 2001; Lavoie et al. 2012; Ranlund et al. 2014)(Andreou, et al., 2015). However, 240 
there is preliminary evidence that CHR+ participants are characterized by elevated frontal 241 
delta, theta- and beta-band power that correlates with increased negative symptoms, a pattern 242 
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that was not observed in the CHR- group that did not develop schizophrenia (Van Tricht et 243 
al., 2014). Moreover, alpha power and alpha peak frequency of resting-state oscillations is 244 
reduced in CHR+ (Van Tricht et al. 2014).  245 
Resting-state activity at beta- and gamma-band frequencies was investigated by Ramyead and 246 
colleagues (2015) who showed that current source density (CSD) estimates of 30-50 Hz was 247 
higher in CHR+ as compared to control participants. Moreover, the authors observed 248 
decreased phase synchrony of beta oscillations in the CHR+ group as compared to controls 249 
and a CHR- group. In further analyses, it was found that increased beta/gamma CSD-250 
estimates strongly contributed to the prediction of psychosis in CHR-participants (Ramyead 251 
et al. 2016). 252 
Moreover, analysis of microstates  has been applied to resting-state EEG-recordings. EEG-253 
microstates can be used to identify short (~ 80-100 ms) quasi-stable brain states through 254 
considering topographies of ongoing electric potentials (Khanna et al., 2014). There are four 255 
standard classes of microstate topography and they have been shown to relate to fMRI 256 
resting-state networks (Koenig et al., 2002; Britz et al., 2010). Previous studies have reported 257 
alterations in resting-state EEG microstate parameters in ScZ patients compared to healthy 258 
controls (for a review see e.g. Rieger et al., 2016), suggesting disturbed information 259 
processing in ScZ patients (e.g. Lehmann et al., 2005). A recent study reported altered EEG 260 
resting-state microstate characteristics in CHRs compared to healthy controls, suggesting that 261 
aberrant resting-state microstates might indicate an increased risk of developing psychosis 262 
(Andreou et al., 2014). 263 
 264 
                                                      Enter Figure 3 about here 265 
 266 
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In addition to resting-state activity, recent studies have examined task-related oscillatory 267 
signatures in CHR-participants. An MEG-study by Koh et al. (2011) reported reduced alpha 268 
event-related desynchronization (ERD) to target tones during an auditory oddball task in 17 269 
CHR individuals. Similar findings were obtained with EEG by Kayser et al. (2014) who 270 
observed a reduction in alpha-ERD that was markedly pronounced in CHR+ participants.  271 
High-frequency oscillations have been investigated in the auditory domain in CHR-272 
participants. Recent studies have shown evidence for a reduction in auditory evoked gamma-273 
band responses (Perez et al. 2014; Leicht et al. 2016). Moreover, there is evidence for 274 
reduced power and phase-synchronization during auditory steady state responses (ASSRs) in 275 
ScZ, in particular to 40 Hz stimulation (Thuné et al. 2016).  A recent study by Tada and 276 
colleagues (2016) assessed 40 Hz ASSRs in 15 CHR individuals, 13 First-Episode (FEP)-277 
patients and 12 healthy controls, indicating reduced power and phase-locking in CHR-278 
participants.  279 
 280 
                                                      Enter Figure 4 about here 281 
 282 
2.3 TMS/tDCS in CHR-Participants  283 
Noninvasive  brain stimulation techniques such as TMS and tDCs are increasingly being used 284 
as tools for investigating the pathophysiology of ScZ (see Agarwal et al. 2013, for a review). 285 
One approach to assess changes in E/I-balance parameters in ScZ is the investigation of 286 
cortical inhibition through TMS in the motor cortex. Short-latency intracortical inhibition 287 
(SICI) assesses intracortical excitability and inhibition by delivering two stimuli (paired 288 
pulses) in a condition-test paradigm and has been associated with the activity of GABAA 289 
receptors (Ziemann 2004; Ziemann et al. 2015). In ScZ patients, there is consistent evidence 290 
for a reduction in SICI, suggesting a disinhibition of motor cortex (Bunse et al. 2014).  291 
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The Contralateral Silent Period (CSP) refers to a sustained decrease in muscle activity found 292 
after single pulse (TMS) stimulation of the motor cortex during active contralateral muscle 293 
contraction and is mediated by GABAB receptors (Werhahn et al. 1999). Several studies have 294 
indicated abnormalities in CSP in ScZ but the direction of the results is conflicting, with 295 
some evidence presented of shortened CSP (Eichhammer et al. 2004; P B Fitzgerald et al. 296 
2002; Paul B Fitzgerald et al. 2002), other results showing prolonged CSP  (Wobrock et al., 297 
2009; Bajbouj et al., 2004; Soubasi et al., 2010). 298 
Finally, short-term effects of anodal Transcranial direct current stimulation (tDCs) have been 299 
used to examine non-invasively long-term-potentiation (LTP) or long-term-depression (LTD) 300 
(Brunoni et al. 2012; Liebetanz et al. 2002). In a recent study by Hasan and colleagues 301 
(Hasan et al. 2011), anodal tDCs-induced plasticity was monitored by TMS-generated motor-302 
evoked potentials (MEP) in a group of recent-onset and chronic ScZ -patients. ME-303 
schizophrenia patients showed significantly reduced LTP-like plasticity compared to RO-304 
patients and healthy controls.  305 
First evidence for alterations in TMS-mediated inhibition parameters in CHR-parameters was 306 
reported by Hasan et al. (2012) who examined SICI and CSP. CHR-participants as well as 307 
FEP-patients showed a reduced SICI response compared to controls, but only the FEP-group 308 
demonstrated a prolonged CSP duration. Thus, it was concluded that GABAA-mediated 309 
processes (linked to SICI) are disturbed earlier in the disorder than GABAB-mediated 310 
mechanisms (linked to CSP).  A more recent study by Tang et al. (2014) showed that 311 
medicated ScZ-patients demonstrated both prolonged CSP as well as attenuated SICI, 312 
whereas CHR-participants only showed prolonged CSP.  313 
 314 
                                                   Enter Figure 4 about here 315 
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3. Magnetic Resonance Spectroscopy in CHR-Participants  316 
 317 
MRS studies of glutamate in ScZ found elevated levels of glutamate or Glx, with significant 318 
increases reported in the thalamus, medial temporal lobe, the basal ganglia (Merritt et al. 319 
2016; Poels et al. 2014) and medial prefrontal cortex (Poels et al. 2014). These increases in 320 
glutamate are consistent with findings of NMDA receptor hypofunctioning in vivo 321 
(Nakazawa, Jeevakumar, and Nakao 2017).  322 
Similar findings have been reported in studies focusing on glutamate or Glx in CHR-323 
participants (Merritt et al. 2016). Significant increases in Glx were found in the medial 324 
prefrontal cortex (Fuente-sandoval et al. 2015), caudate (Fuente-Sandoval et al. 2011; Tandon 325 
et al. 2013) and thalamus (Tandon et al. 2013). However, decreased glutamate levels have 326 
been reported in the thalamus (P. Fusar-Poli 2011) or no difference in glutamate or glx 327 
concentrations (Natsubori et al. 2014; Wood et al. 2010; Yoo et al. 2009). 328 
So far, 1H-MRS measures of GABA in ScZ have been inconclusive in established ScZ 329 
(Wijtenburg et al. 2015; Egerton et al. 2017). A recent meta-analysis by Egerton and 330 
colleagues (2017) suggested that across studies, there is no evidence for change in GABA-331 
levels. However, it should be note that changes have been observed that support either an 332 
increase (Kegeles et al. 2012; Tayoshi et al. 2010; Öngür, Prescot, and McCarthy 2010; 333 
Rowland et al. 2013) or a decrease of GABAergic neurotransmission (Marenco et al. 2016; 334 
Menschikov et al. 2016; Yoo et al. 2009). Differences between studies could potentially be 335 
attributed to methodological parameters, illness-stage as well as selection of ROIs.  336 
Accordingly, increases in GABA-levels similar to those observed in ScZ have also been seen 337 
in the medial prefrontal cortex and dorsal caudate of CHR-participants (Fuente-sandoval et 338 
al. 2015). In contrast, Menschikov et al. reported decreased GABA and a decreased 339 
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GABA/Glx ratio in left anterior cingulate cortex of CHR-participants (Menschikov et al. 340 
2016). 341 
 342 
4. Discussion 343 
 344 
The development of insights into circuit changes that underlie the emergence of psychosis 345 
and cognitive deficits in ScZ remains one of the most urgent challenges in mental health 346 
research. This is because of limited progress in recent decades in the development of novel 347 
interventions that improve outcome in the majority of ScZ-patients. Accordingly, the 348 
possibility to identify at-risk individuals prior to the onset of psychosis could potentially 349 
allow the delay or even prevention of the full expression of psychosis and associated 350 
disability if treatments become available that target mechanisms underlying the development 351 
of ScZ.  352 
The current paper aimed to provide a comprehensive overview on neuronal dynamics in at-353 
risk individuals for psychosis to establish whether alterations in neural oscillations and 354 
ERPs/ERFs and underlying generating mechanisms are already present in CHR-participants. 355 
Evidence has emerged that the pronounced cognitive dysfunctions as well as certain clinical 356 
symptoms in ScZ may be the result of aberrant communication between and within neuronal 357 
assembles that can be captured through electrophysiological measurements of neural 358 
oscillations and event-related fields (Stephan, Friston, & Frith, 2009; Uhlhaas & Singer, 359 
2010). Moreover, such disturbances are thought to be the consequence of alterations in E/I-360 
balance parameters which are important aspects for proper gating of information during 361 
normal brain functioning (Haider and McCormick 2009) and for the generation of high- 362 
frequency oscillations (Sohal et al., 2009; Whittington, et al., 1995). Importantly, these 363 
parameters also allow mechanistic insights into the origin of these circuit dysfunctions 364 
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through links with pre-clinical research and thus offer opportunities for the development of 365 
novel, more effective and pre-emptive interventions (Uhlhaas & Singer, 2012).  366 
 367 
4.1 Neural Dynamics and Biomarkers for Prediction  368 
A crucial prerequisite for this endeavour is the identification of biomarkers that allow on the 369 
one hand insights into the causes of emerging cognitive deficits and psychosis and, on the 370 
other hand, are suitable for risk-stratification at the individual level to predict clinical 371 
outcomes. This is because the current criteria for the diagnosis of CHR-status convey risk for 372 
a range of mental health outcomes in young people, including ScZ, affective disorders, 373 
personality disorders (Lin, et al., 2015). Moreover, a substantial number of individuals 374 
fulfilling CHR-criteria will remain without any symptomatic complaints, highlighting the 375 
need to improve on current risk-prediction that is largely based on clinical measures.  376 
Novel algorithms that combine clinical, demographical and neuropsychological information 377 
have shown that risk-prediction can be significantly improved over existing data that largely 378 
rely on information based on clinical information alone (Cannon, et al., 2016). Accordingly, 379 
it remains an open question whether biomarkers obtained through EEG/MEG-parameters 380 
perform significantly better or enhance risk-algorithms if they are combined with clinical and 381 
neuropsychological data.  382 
Among the most consistent findings in CHR-participants are abnormalities in pre-attentive 383 
auditory processing as reflected by the MMN-potential which may also predict onset of 384 
psychosis (for a review see Bodatsch et al., 2015). Oscillatory activity has been examined in 385 
both task-related and spontaneous contexts in CHR-participants. Reductions in gamma-band 386 
activity during auditory stimulation have been reported (Leicht et al., 2016; Perez et al., 387 
2014a, Tada et al., 2016) that replicate a large body of work in established ScZ, indicating 388 
that neural circuits are impaired in the generation of high-frequency oscillations (Grent-'t-389 
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Jong, et al., 2016; Kwon, et al., 1999; Spencer, et al., 2004). However, it is currently unclear 390 
whether auditory gamma-band oscillations are potential predictors for psychosis 391 
development. Preliminary data from resting-state oscillations suggests that aberrant, 392 
spontaneous high-frequency oscillations potentially indicate a higher risk for transition to 393 
psychosis (Ramyead et al. 2015, 2016), but further data are required to replicate this findings.  394 
An important test therefore of the framework proposed here are further studies into the ability 395 
to predict clinical outcome in CHR-participants using time-frequency and ERP/ERF-data. 396 
Currently, only a relatively small amount of studies have tested the possibility of predicting 397 
psychosis-onset based on information from the EEG/MEG-parameters, especially in regards 398 
to the possibility of using neural oscillations as a biomarker for the prediction of psychosis in 399 
CHR-groups.  400 
 401 
4.2 Circuit Dysfunctions and the Pathophysiology of the Prodrome  402 
Emerging evidence from MRS and brain stimulation highlight that the disruption of ERPs 403 
and neural oscillations could potentially be due to alterations in E/I-balance parameters. This 404 
is supported by reduced inhibitory cortical transmission as revealed by TMS/tDCS (Hasan et 405 
al. 2012; Tang et al. 2014) as well as by elevated Glutamate levels in MRS-measurements in 406 
CHR-participants cortex (Fuente-sandoval et al., 2011, 2015; Tandon et al., 2013), suggesting 407 
that emerging cognitive deficits as well as psychosis could result from disturbances in 408 
GABAergic and Glutamatergic neurotransmission.  409 
This hypothesis is consistent with impairments in MMN-deficits in CHR-participants 410 
(Bodatsch, Brockhaus-Dumke, Klosterkotter, & Ruhrmann, 2015) that together with the 411 
extensive evidence from studies into established ScZ (Erickson, Ruffle, & Gold, 2016) 412 
suggests that the MMM and its neuromagnetic counterpart constitutes currently one of the 413 
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most promising biomarkers for ScZ. Among the generating mechanisms that have been 414 
implicated in MMN-parameters, involvement of NMDA-Rs (Javitt, Steinschneider, 415 
Schroeder, & Arezzo, 1996) as well as SST-interneurons (Hamm & Yuste, 2016) have been 416 
demonstrated.  417 
A related finding that points towards circuit anomalies in auditory regions in CHR-418 
participants is the emerging evidence on the failure to generate gamma-band oscillations 419 
(Tada, et al., 2016). Given the mechanistic role of PV+ interneurons in the emergence of 420 
rhythmic activity at gamma-band frequencies (Sohal, et al., 2009), an obvious candidate 421 
mechanism are the impairments in GABAergic neurotransmission. As highlighted previously, 422 
however, it is currently unclear whether dysfunctions in PV+ interneurons represent a 423 
primary pathophysiological process or a downstream consequence of deficits in excitatory 424 
pyramidal cell activity and/or oxidative stress (Lewis, et al., 2012; Steullet, et al., 2017).  425 
This question also highlights that it will remain challenging to develop mechanistic insights 426 
into the origins of circuit dysfunctions in ScZ based on non-invasive electrophysiology, 427 
neuroimaging and brain stimulation data alone. This is because the disruptions in neural 428 
oscillations and ERP/ERF-parameters may represent endpoints of developmental 429 
disturbances that can arise from different etiologies. Accordingly, it is imperative that 430 
EEG/MEG-approaches are integrated with basic in-vitro and in-vivo studies into the origin 431 
and mechanistic role of E/I-balance disturbances in order to arrive at a neurobiologically 432 
informed understanding of cognitive dysfunctions and emerging psychosis.  433 
 434 
4.3 Neurodynamics and the Treatment of Prodromal Schizophrenia  435 
This approach could offer a novel approach towards the treatment of ScZ that so far has 436 
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largely relied on the assumption that dopaminergic abnormalities are leading to psychosis and 437 
certain cognitive impairments (Howes & Kapur, 2009). However, given the fact that 438 
antipsychotic treatments have not substantially improved the more fundamental cognitive 439 
deficits nor negative symptoms of the disorder, it is possible that addressing alternative 440 
circuit mechanisms that are crucial for neuronal dynamics has great potential for advancing 441 
treatment and therefore clinical outcomes.  442 
Preliminary evidence from a study by Kantrowitz et al. (2015) suggests that modulation of 443 
NMDA-Rs in CHR-participants may represent a viable strategy for novel treatment 444 
approaches. Administration of D-Serine, a NMDA-R agonist, significantly improved negative 445 
symptoms in a small sample of participants meeting CHR-criteria. Related evidence from the 446 
same investigators has shown that D-Serine also improves MMN-generation in chronic ScZ-447 
patients (Kantrowitz, et al., 2016). 448 
Another therapeutic target are impairments in oxidative stress that have been identified as a 449 
common factor in several animal models of ScZ and contribute to PV+ interneuron deficits 450 
and NMDA-R hypofunctioning (Steullet, et al., 2017). Administration of the antioxidant N-451 
acetyl cysteine (NAC) in established ScZ has been shown to improve MMN-deficts as well as 452 
negative symptoms Do (Lavoie, et al., 2008). Related to the possibility of using NAC for the 453 
treatment of prodromal ScZ, Cabungcal et al.  (2014) examined NAC to target the emergence 454 
of cognitive deficits in the neonatal ventral hippocampal lesion (NVHL) rodent model of 455 
ScZ. Administration of NAC in adolescent rats prevented the reduction of PV+ interneuron 456 
deficits in the PFC as well as electrophysiological and behavioral deficits observed in ScZ-457 
patients, highlighting the potential of preventive treatments that target E/I-balance .for 458 
correction circuit abnormalities prior to the onset of ScZ.  459 
Brain stimulation may represent an additional, emerging approach that could be harnessed in 460 
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the future to correct abnormalities in neural dynamics. Specifically, it is conceivable that 461 
aberrant oscillatory activity is targeted to with brain stimulation techniques, such as tACS and 462 
TMS, as evidence suggests that brain networks can be entrained at specific frequencies (Thut, 463 
Schyns, & Gross, 2011) This approach has been tested in in-vitro and in-vivo animal research 464 
as well as in human studies, all pointing towards converging evidence for the effectivity of 465 
the approach (Frohlich & McCormick, 2010; Ozen, et al., 2010)(Helfrich, et al., 2014).  466 
 467 
Summary and Outlook  468 
The current data provide preliminary support for the hypothesis that the prodrome of ScZ is 469 
associated with aberrant neuronal dynamics. Because of the possibility to link these 470 
parameters to basic circuit mechanisms, we believe that it is important to carry out further 471 
studies using advanced EEG/MEG-approaches that fully exploit advances in signal 472 
processing and source-reconstruction techniques to capture alterations in the spectral 473 
signatures and organization of large-scale networks. Together with systematic links with 474 
translational research, we believe that this approach could potentially lead to paradigm-475 
changing approach in ScZ towards early intervention and treatment.  476 
 477 
 478 
 479 
 480 
 481 
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 486 
Figure Legends 487 
 488 
Figure 1: Model of psychosis onset from the clinical high-risk state. Self-experienced 489 
perceptual and cognitive abnormalities are considered to be earliest sign-posts for psychosis 490 
risk prior to the development of sub-threshold psychosis symptoms. (adapted from Fusar-Poli 491 
et al., 2013).  492 
Figure 2: MMN-Findings in ScZ and Clinical High Risk Groups: a) Mean effect size and 493 
95% confidence interval by group for MMN-deficits in ScZ, Bipolar, CHR- and first-degree 494 
relatives. CI, confidence interval; SZ, schizophrenia. (adapted from Erickson et al., 2015).  495 
b) Duration MMN in CHR-participants. The solid black line represents the duration MMN in 496 
healthy controls, the solid gray line depicts the duration MMN in FEP-patients. HC, healthy 497 
control subjects; AR, at-risk subjects; FES, first-episode schizophrenia.  498 
c) Relationship between MMN-deficits and transition to psychosis. Hazard function of the 499 
two risk classes generated by a median split. Cumulative hazard rate in Class 1 (dotted line) 500 
is .34 and .85 in Class 2 (solid line). Follow-up periods exceeding 24 months were considered 501 
at the end of Month 24. (adapted from Bodatsch et al., 2011). 502 
 503 
 504 
Figure 3: ASSR-Findings in ScZ and Clinical High Risk Groups: a) Meta-Analysis of 40 Hz 505 
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ASSR in ScZ. Hedges g random-effect sizes for 20 studies, showing power and phase effects 506 
separately. Across studies, the Hedges g random-effect size was −0.46 for phase measures 507 
and −0.58 for power measures. For both measures combined, the overall effect size was 508 
−0.50.  509 
b) EEG 40 Hz ASSR-data in CHR-participants. Left panel: Figure 2. Time course of the 40-510 
Hz ITC. The x-axis indicates time (ms), and the y-axis indicates ITC. The blue line, dotted 511 
line, and purple line indicate the 40-Hz ITC in healthy controls, ultra-high risk, and FEP 512 
schizophrenia, respectively. Right Panel: The time course of the 40-Hz ERSP. The x-axis 513 
indicates time (ms), and the y-axis indicates ERSP. The blue line, dotted line, and purple line 514 
indicate the 40-Hz ERSP in healthy controls, ultra-high risk, and first-episode schizophrenia, 515 
respectively. (adapted from Tada et al., 2016).  516 
c) 40 Hz ASSR and NMDA-R modulation: Heat map representation of mean PLF measure at 517 
the 7 min point following vehicle (a) or ketamine [1 (b) or 30 (c) mg/kg] treatments. Dashed 518 
boxes indicate computed activity within the gamma band (35–45 Hz) for the duration of the 519 
stimulus train (0.5 s). In comparison to the vehicle group, note a clear increase after 1 mg/kg 520 
ketamine treatment and a reduction after 30 mg/kg treatment. Statistical significance 521 
indicated by *Po0.05; Dunnett’s test. (adapted from Sivarao et al., 2016)  522 
 523 
 524 
Figure 4. MRS Glutamate Findings in ScZ and Clinical High Risk Groups 525 
a) Overview of MRS Glutamate findings in ScZ. Negative Hedges g values denote lower 526 
glutamatergic metabolite concentrations in cases than controls; positive values denote higher 527 
glutamatergic metabolite concentrations in cases than controls. The size of the data markers is 528 
proportional to the total number of individuals. DLPFC indicates dorsolateral prefrontal 529 
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cortex; Glx, combined glutamate and glutamine signal; MTL, medial temporal lobe; and 530 
WM, white matter. (adapted from Merritt et al., 2016). 531 
b) MRS Glutamate findings in CHR-participants. Location of voxel placement for MRS 532 
acquisition and glutamate levels in the region of interests: left hippocampus (upper left), 533 
anterior cingulate (upper right), right thalamus (lower left). Error bars show the 95% 534 
confidence intervals of the means. ARMS indicates at-risk mental state. (adapted from (P. 535 
Fusar-Poli 2011). 536 
 537 
 538 
 539 
 540 
 541 
 542 
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